Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

HNL Lab Medicine investment to enhance diagnostic capabilities

Proscia
By Author Proscia | July 18, 2023

“We are excited to embark on this digital pathology journey with Proscia and Leica Biosystems,” said Dr. Jordan Olson, Medical Director of HNL Lab Medicine. “We chose Leica Biosystems as our whole slide imaging vendor due to their high image quality and demonstrated ability to handle large volumes. We selected Proscia’s Concentriq Dx* as our digital pathology platform because it aligns with HNL Lab Medicine’s vision for innovation and efficiency.” 

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US under the COVID-19 enforcement policy for remote pathology devices.

Our website uses cookies. By using this site, you agree to its use of cookies.